“uniqure” Archives

in
Entry Author Date Location
Freeline Therapeutics and Checkmate Pharma Make Opening IPO Moves 07/21/20 Europe
Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More 06/26/20 National
CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy 06/25/20 Philadelphia
Triplet Therapeutics Unveils $59M to Try Hairpin Fix for Huntington’s 12/17/19 Boston
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More 08/23/19 National
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More 07/12/19 National
The Finalists for the 2019 Xconomy Awards Are … 07/10/19 Boston
Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More 06/21/19 National
After AGTC Deal Flops, Biogen Bets $800M on Gene Therapy Rival Nightstar 03/04/19 Boston
Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy 02/25/19 National
15 for ’19: Key Clinical Data to Watch for Next Year (Part 1) 12/17/18 National
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More 11/16/18 National
Data Starts Stretch Run for UniQure’s Upgraded Hemophilia Gene Therapy 11/15/18 Boston
Bio Roundup: Brii Does China, Hemophilia Updates, Right to Try & More 05/25/18 National
As Novartis Buys In to Gene Therapy, GSK Bows Out with Orchard Deal 04/12/18 Boston
Spark CEO Marrazzo on Gene Therapy Pricing & Paving the Way for the Field 01/12/18 National
Gene Therapy 2.0: New Startups Aim to Fine-Tune Gene Delivery and Control 01/04/18 Boston
FDA OKs Spark’s Gene Therapy for Rare Blindness, But No Price in Sight 12/19/17 National
Bio Roundup: Kite’s CAR-T Approved, Obamacare Fix & Lilly mRNA Deal 10/20/17 National
For Key Study, UniQure Allowed to Swap Hemophilia Gene Therapies 10/19/17 Boston
LogicBio Lands $45M for Gene Therapies in Rare Pediatric Diseases 06/28/17 Boston
Bluebird Reports Early Results From Upgraded Gene Therapy 06/23/17 Boston
Bio Roundup: Spinraza Woes, Science March, Baseline Launch & More 04/21/17 National
UniQure to Yank Pioneering Gene Therapy From Market in Europe 04/20/17 Boston
His Gene Therapy Near Approval, Spark CEO Wonders: What Price Vision? 02/16/17 New York
Investors Sour on Data Debut For Dimension’s Hemophilia Gene Therapy 01/31/17 Boston
14 For ’17: Key Clinical Data to Watch For Next Year (Part 1) 12/21/16 National
ASH Roundup: CAR-T Shuffle, Hemophilia Updates, Checkpoint Progress & More 12/06/16 National
Fresh Off ASH Data, Spark Teams With Selecta to Boost Gene Therapies 12/05/16 Boston
Bio Roundup: Trump’s Rx Silence, PCSK9 News, Amgen’s Migraines & More 11/18/16 National
Page 1 of 2 next page »